Catalyzing New Health Innovation Technologies

From Hit to Hope — Accelerating Discovery with Precision

We specialize in pre-clinical drug discovery and development. We specialize in hit identification, lead optimization, custom synthesis and testing — enabling academic and industry breakthroughs in drug discovery.

Your Partner in Innovation

Transforming Ideas into Solutions

We provide expert scientific consultation for academic and industrial partners on early discovery strategies, compound design, optimization, and translational pipelines.

Our Mission

CANHIT Therapeutics Inc. is dedicated to transforming early-stage drug discovery by bridging cutting-edge science with practical solutions. Through the convergence of AI, molecular modeling, medicinal chemistry, and bioanalytical expertise, we deliver high-impact molecules, novel throughput assays, and technologies that fuel the next generation of therapeutics. Our mission is to empower researchers and industry partners with innovative tools and promising leads that accelerate discovery and improve lives.

About us

We are a multidisciplinary team of scientists, engineers, and innovators dedicated to accelerating drug discovery. With deep expertise in computational biology, chemistry, and AI-driven design, we combine cutting-edge science with a passion for solving complex health challenges. Our mission is to transform promising ideas into real-world therapeutics that improve lives.

Dr. Aravindhan Ganesan Ph.D.

Director, Drug Discovery R&D

Dr. Praveen Nekkar Rao Ph.D.

Director, Medicinal Chemistry R&D

Dr. Subha Kalyaanamoorthy Ph.D.

Director, AI and Protein Engineering R&D

Research & Development

Intrinsically disordered proteins -Neurodegenerative disorders

Our research addresses the complex molecular mechanisms underlying neurodegenerative diseases, with a particular focus on intrinsically disordered proteins (IDPs) and their aggregation. These proteins, which lack a stable three-dimensional structure, present significant challenges for conventional drug discovery due to their dynamic and heterogeneous nature. We investigate the aggregation mechanisms of IDPs and identify aggregation-prone regions that drive disease pathology. Leveraging these insights, we develop novel diagnostics and therapeutics to target toxic protein assemblies. Our expertise includes the design of engineered peptides, small molecules, nanoparticles, and targeted chimeras. Using our state-of-the-art in silico and in vitro pipelines, we have successfully generated a broad range of protein aggregation inhibitors. Our strategies span a wide spectrum of neurodegenerative disorders, with the goal of enabling earlier detection and more effective therapeutic intervention.

Our team focuses on targeting disease-relevant enzymes through the design and development of novel inhibitors. Enzymes play critical roles in numerous pathological processes, and their dysregulation is a hallmark of many diseases, including cancer, metabolic disorders, infectious diseases, and neurodegeneration. Leveraging our proprietary screening platforms, which combine structure-based, ligand-based, and AI-enabled virtual high-throughput screening, with rapid and efficient biochemical assay development, we accelerate the discovery of selective and potent inhibitors. These inhibitors serve not only as promising therapeutic candidates but also as valuable molecular probes to deepen our understanding of disease mechanisms.

Enzyme Inhibition

Artificial Intelligence-Enabled Protein Design and Engineering

We offer cutting-edge protein engineering services tailored for both therapeutic and industrial applications, combining traditional rational and semi-rational design approaches with the latest advances in deep learning and protein language models. Our integrated platform leverages structural insights and computational predictions to design proteins with enhanced stability, activity, and specificity. By harnessing AI-driven models trained on vast protein sequence and structural data, we accelerate the identification of beneficial mutations and optimize protein function beyond conventional methods. Whether you seek novel enzymes for biocatalysis, improved therapeutic proteins, or tailored binding affinities, our expertise enables efficient, data-driven engineering to meet your unique project goals.

Our research focuses on the in silico design of PROTACs (proteolysis-targeting chimeras) and other targeted protein degraders that reprogram cellular machinery for selective protein knockdown. By integrating molecular docking, molecular dynamics, and AI-driven modeling, we design and optimize chimeric molecules that bring target proteins into proximity with E3 ligases or other effector systems. Our platform enables rapid exploration of linker composition, spatial orientation, and ternary complex stability to predict degradation efficiency and selectivity. We are expanding this approach beyond traditional PROTACs to develop novel bifunctional modalities for previously undruggable targets.

Services

Innovative solutions in drug discovery and health technologies development.

Contract Services

Training Services

Empowering minds with real-world skills.

Consultancy Services

Expert advice that drives discovery forward.

From concept to compound—science that delivers.

We offer a comprehensive suite of services to support every stage of the drug discovery pipeline. Our Contract Services include hit discovery, protein engineering, chemical synthesis, medicinal chemistry, bioassay development, and DMPK studies—delivered with precision and scientific rigor.

Our team offers expert consultancy to help guide your drug discovery efforts with clarity and confidence. Whether you need support in experimental design, project strategy, or navigating technical challenges, we provide tailored advice grounded in cutting-edge science and industry insight. From early-stage innovation to late-stage optimization, we work closely with clients to accelerate progress and maximize impact.

We offer customized training programs designed to build practical skills and deepen scientific understanding across all areas of drug discovery. From task-specific training and hands-on workshops to in-depth courses and guest lectures, our programs are tailored to meet the needs of academic researchers, industry professionals, and trainees. Whether you're looking to upskill your team or introduce new technologies, we deliver impactful learning led by experienced scientists.

Contact Us

We're here to collaborate, innovate, and accelerate your discovery goals. Contact us to explore how our expertise in drug discovery and protein engineering can support your next breakthrough.